EUVIMED · CrossrefJournal
Expert Opinion on Investigational Drugs
ISSN 1354-3784 · Informa UK Limited
Latest articles
VERVE‑102: Next‑generation PCSK9 base‑editing for durable LDL‑cholesterol reduction
Novel and emerging agents for myelodysplastic syndromes/neoplasms
Emerging synthetic biology toolkits to control gene expression and provide therapeutic avenues in cardiovascular disease
Are we moving forward from amisulpride? LB-102 ( N- methyl amisulpride) in acute schizophrenia
Targeted KIT inhibitors: paradigm shift in the treatment of systemic mastocytosis
Targeting MUC1 in colorectal cancer
Innovative therapies under clinical development for ALS treatment. Part 2: biologics and natural products
Emerging therapeutic strategies and clinical development of investigational agents for conventional chondrosarcoma
Safety, pharmacokinetics, pharmacodynamics and target-mediated drug disposition modeling of TST002, a sclerostin antibody, in men and postmenopausal women with low bone mineral density
Dual antigen targeting in extramedullary multiple myeloma
Evaluating early systemic therapies in the neoadjuvant setting for the treatment of urological cancers
Targeting the proteasome in Leishmania donovani : developments from preclinical to Phase I and II trials
ANGPTL3 gene editing with CRISPR-Cas9: early trial insights
Odronextamab: a bispecific antibody for follicular lymphoma
Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights
Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis
Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?
Elezanumab for the treatment of spinal cord injury: assessing the clinical development journey to date
Advancements in longevity pharmacology research – are we finally seeing clinical progression?
The impact of novel BET inhibitors on the treatment armamentarium of myelofibrosis
Alpha-1 antitrypsin: therapeutic applications beyond serine protease inhibition
SOT201: cis -acting PD-1/IL-15 mutein-based immunocytokine under investigational study in solid tumors
The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugates
Evaluating the investigational drug landscape for ESR1 -mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer
Safety, tolerability, and pharmacokinetics of HL-300, a novel topical pan-JAK inhibitor, in healthy Chinese adults: a first-in-human, randomized, double-blind, placebo-controlled phase I trial
Darigabat and subtype-selective GABA-A modulation: pharmacology, clinical development, and translational challenges
Isatuximab: an anti-CD38 therapy that addresses unmet needs and mechanisms of resistance in multiple myeloma
Tafoxiparin effects on cervical ripening and labor augmentation
A novel sequential ketamine and D-cycloserine/lurasidone therapy for bipolar depression with acute suicidal ideation
New insights into the management of Behçet syndrome
Volumes
2026 · 792025 · 862024 · 1102023 · 1082022 · 1062021 · 1162020 · 1322019 · 1052018 · 952017 · 1402016 · 1282015 · 1452014 · 1552013 · 1522012 · 1652011 · 1452010 · 1492009 · 1682008 · 1792007 · 1712006 · 1412005 · 1372004 · 1872003 · 3042002 · 1332001 · 1632000 · 2081999 · 1551998 · 1501997 · 1471996 · 1321995 · 1271994 · 1211993 · 1691992 · 14
EUVIMED